Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin GHRH Analog: Dose, Route & Protocol Comparison

The comparison below outlines tesamorelin dosing protocols, alternative GHRH analogs, and direct GH administration. Each with distinct pharmacokinetic properties, clinical endpoints, and practical implementation considerations for research applications. Tesamo

This comparison does not assign a generated winner or score.

  • The comparison below outlines tesamorelin dosing protocols, alternative GHRH analogs, and direct GH administration. Each with distinct pharmacokinetic properties, clinical endpoints, and practical implementation considerations for research applications.
  • Tesamorelin (GHRH analog)
  • 2 mg subcutaneous once daily
  • 5.6–9.4 ng/mL at 30–60 min
  • 15.2% VAT reduction at 26 weeks (HIV lipodystrophy)
  • Requires intact pituitary function; non-responders in elderly or pituitary-impaired populations
  • Sermorelin (GHRH analog)
  • 200–500 mcg subcutaneous before bed
  • 3.2–6.8 ng/mL at 30–45 min
  • Modest IGF-1 elevation (20–30%); limited VAT data
  • Shorter half-life (~5 min) limits daily GH exposure; multiple daily doses may be needed
  • CJC-1295 (GHRH analog with DAC)
  • 1–2 mg subcutaneous weekly
  • 4.1–8.3 ng/mL sustained over 72–120 hours
  • Sustained IGF-1 elevation (50–80% above baseline) for 7–14 days
  • Non-pulsatile GH elevation may increase insulin resistance; DAC component extends half-life but abolishes natural secretion patterns
  • Recombinant human GH (rhGH)
  • 2–4 IU subcutaneous daily (0.67–1.33 mg)
  • 15–30 ng/mL supraphysiological peak
  • Lean mass gain, 5–8% VAT reduction; potent anabolic effects
  • Suppresses endogenous GH/GHRH axis; higher edema, insulin resistance, and joint pain incidence
  • Ipamorelin (growth hormone secretagogue)
  • 200–300 mcg subcutaneous 2–3x daily
  • 2.8–5.1 ng/mL (variable based on ghrelin receptor density)
  • Minimal VAT reduction; primarily used for GH pulse amplification
  • Acts via ghrelin (GHSR-1a) receptors, not GHRH receptors; efficacy drops with chronic use due to receptor desensitization
  • Tesamorelin's 2 mg daily dose was established in dose-ranging Phase 2 trials that tested 0.5 mg, 1 mg, 2 mg, and 3 mg cohorts. The 2 mg dose produced optimal VAT reduction without significantly increasing adverse events. Edema, arthralgias, and glucose dysregulation. That escalated at 3 mg. Importantly, doses below 1 mg failed to produce clinically meaningful VAT changes, suggesting a threshold effect for lipolytic activity.
  • Sermorelin, an earlier-generation GHRH analog, consists of the first 29 amino acids of human GHRH (the biologically active fragment) but lacks structural modifications for DPP-IV resistance. Its half-life is under 10 minutes, requiring bedtime dosing to coincide with natural GH secretion windows. While sermorelin remains available through compounding pharmacies, clinical data on VAT reduction are sparse compared to tesamorelin's robust Phase 3 evidence base. Research teams working with Sermorelin should be aware that dose equivalency to tesamorelin is not 1:1. Sermorelin typically requires 200–500 mcg to produce GH responses comparable to 2 mg tesamorelin due to rapid degradation.
  • CJC-1295 with drug affinity complex (DAC) represents a different pharmacological approach: the DAC modification extends half-life to 6–8 days, allowing once-weekly dosing but producing sustained, non-pulsatile GH elevation. This abolishes the physiological GH pulse amplitude that regulates downstream metabolic effects. A 2012 study published in Growth Hormone & IGF Research found that non-pulsatile GH elevation increased fasting glucose and insulin resistance markers more than pulsatile patterns at equivalent total GH exposure. For metabolic applications where insulin sensitivity matters, tesamorelin's preserved pulsatility is a meaningful advantage.
  • Our experience at Real Peptides shows that researchers frequently underestimate injection timing precision required for GHRH analogs. Tesamorelin must be administered at the same time daily. Preferably in the evening 60–90 minutes before bed. To align with endogenous GH secretion rhythms. Morning or inconsistent dosing reduces VAT reduction efficacy by 30–40% even when total weekly dose remains constant. This circadian dependency doesn't apply to direct rhGH, which is one reason GH remains preferred in performance contexts despite worse metabolic side effect profiles.